---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-055041"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:34:59.269284+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NRx receives default notice on $6.5M note; reports promising NRX-101 trial data vs lurasidone

## Summary
- Streeterville Capital alleges default on $11.02M convertible note; demands acceleration and repayment of at least $6,537,027.
- Company disputes the claim, says spin-off of Hope Therapeutics is not a Fundamental Transaction, and will defend vigorously.
- Phase 2b/3 trial: NRX-101 showed 33% advantage in sustained remission of suicidality vs lurasidone (not statistically significant at this sample size).
- NRX-101 showed 75% advantage in relief from akathisia (P=0.076), a side effect linked to suicide; both signals met promising zone criteria.
- Company plans 300-patient registrational trial; believes NRX-101 could be the first oral antidepressant to reduce suicide risk.

## SEC filing metadata
- accession: 0001104659-24-055041
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.04, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465924055041/0001104659-24-055041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465924055041/tm2413153d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-055041
- JSON: https://secwatch.observer/filing/0001104659-24-055041.json
- Plain text: https://secwatch.observer/filing/0001104659-24-055041.txt

## Key facts
- Debt Financings
  NRX Pharmaceuticals, Inc. faced acceleration on convertible notes of $11,020,000.00 with Streeterville Capital, LLC.
  - Instrument: convertible notes
  - Principal: $11,020,000.00
  - Counterparty: Streeterville Capital, LLC
  - Event: acceleration
  source text: Note (the "Note") dated November 4, 2022 issued by NRX Pharmaceuticals, Inc., a Delaware corporation ("Borrower"), in favor of Lender, in the original principal amount of $11,020,000.00, as amended by that certain Amendment to Convertible Promissory Note dated March 30, 2023 ("Amendment #1"), that certain Amendment #2 to Convertible Promissory Note dated July
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465924055041/0001104659-24-055041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.